Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elizabeth Bortolon"'
Autor:
Donglu Zhang, Bin Ma, Peter S. Dragovich, Li Ma, Shu Chen, Eugene C. Chen, Xiaofen Ye, Joyce Liu, Jennifer Pizzano, Elizabeth Bortolon, Emily Chan, Xing Zhang, Yi-Chen Chen, Elizabeth S. Levy, Robert L. Yauch, S. Cyrus Khojasteh, Cornelis E. C. A. Hop
Publikováno v:
Communications Medicine, Vol 4, Iss 1, Pp 1-14 (2024)
Abstract Background Proteolysis-targeting chimeras (PROTACs) are being developed for therapeutic use. However, they have poor pharmacokinetic profiles and their tissue distribution kinetics are not known. Methods A typical von Hippel-Lindau tumor sup
Externí odkaz:
https://doaj.org/article/d01205e636654c30909bf31520a8b785
Autor:
Jennifer Cantley, Xiaofen Ye, Emma Rousseau, Tom Januario, Brian D. Hamman, Christopher M. Rose, Tommy K. Cheung, Trent Hinkle, Leofal Soto, Connor Quinn, Alicia Harbin, Elizabeth Bortolon, Xin Chen, Roy Haskell, Eva Lin, Shang-Fan Yu, Geoff Del Rosario, Emily Chan, Debra Dunlap, Hartmut Koeppen, Scott Martin, Mark Merchant, Matt Grimmer, Fabio Broccatelli, Jing Wang, Jennifer Pizzano, Peter S. Dragovich, Michael Berlin, Robert L. Yauch
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
SMARCA2 has been identified as a synthetic lethal target in SMARCA4 mutated tumors, however, homology between the two has hindered the development of selective SMARCA2 inhibitors. Here, the authors synthesize a proteolysis targeting chimera (PROTAC)
Externí odkaz:
https://doaj.org/article/8a0e9dc628914f238a2a801adba2571a
Autor:
Ponien Kou, Elizabeth S. Levy, An D. Nguyen, Donglu Zhang, Shu Chen, Yusi Cui, Xing Zhang, Fabio Broccatelli, Jennifer Pizzano, Jennifer Cantley, Elizabeth Bortolon, Emma Rousseau, Michael Berlin, Peter Dragovich, Vijay Sethuraman
Publikováno v:
Pharmaceutics, Vol 15, Iss 8, p 2098 (2023)
Proteolysis-Targeting Chimeras (PROTACs) are a promising new technology in drug development. They have rapidly evolved in recent years, with several of them in clinical trials. While most of these advances have been associated with monovalent protein
Externí odkaz:
https://doaj.org/article/8e4f9f68f9ea427e99c4b7d4b7e93010
Autor:
Kathryn Smith, Andrea Lopez-Arroyo, Jason Berk, Peter Hegan, Peter Nower, Samantha Tice, Aurelie Moutran, Jennifer Pizzano, Amanda Dowtin, Mark Bookbinder, Elizabeth Bortolon, Greg Cadelina, Fazlul Karim, Katie Digianantonio, Miklos Bekes, Jesus Medina
Publikováno v:
Molecular Cancer Research. 21:PR09-PR09
KRAS is genomically altered in about one third of all human tumors. Due to its central role in oncogenesis, many attempts have been made in the last four decades to drug mutant KRAS, either directly or indirectly. Despite recent advances in targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6662ff725ab919eef766a4181d81492
https://doi.org/10.1158/1557-3125.ras23-pr09
https://doi.org/10.1158/1557-3125.ras23-pr09
Autor:
Jessica Teh, Elizabeth Bortolon, Jennifer Pizzano, Melissa Pannone, Sean Landrette, Richard Gedrich, Ian Taylor
Publikováno v:
Cancer Research. 83:3075-3075
ARV-471 is a selective, orally bioavailable PROteolysis-TArgeting Chimera (PROTAC®) small molecule that induces wild-type and mutant estrogen receptor (ER) alpha degradation via the ubiquitin-proteasome system. ARV-471 demonstrates superior ER degra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0369c20d4aacafe52e14600c76ec11cd
https://doi.org/10.1158/1538-7445.am2023-3075
https://doi.org/10.1158/1538-7445.am2023-3075
Autor:
Jessica Teh, Shannon Bessonett, Wendy Wu, Christopher Kuhlberg, Alissa Wynne, Sean Landrette, Monica Andreoli, Elizabeth Bortolon, Jennifer Pizzano, Richard Gedrich, Ian Taylor
Publikováno v:
Cancer Research. 83:432-432
ARV-471 is an orally bioavailable cereblon (CRBN)-based PROteolysis-TArgeting Chimera (PROTAC®) small molecule that demonstrates superior ER degradation and anti-tumor activity compared to fulvestrant in endocrine sensitive and resistant xenograft m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bdc3ef8407fdf3b86e62f8c39331341
https://doi.org/10.1158/1538-7445.am2023-432
https://doi.org/10.1158/1538-7445.am2023-432
Autor:
Robert Yauch, Jennifer Cantley, Xiaofen Ye, Emma Rousseau, Tom Januario, Brian Hamman, Chris Rose, Tommy Cheung, Trent Hickle, Leofal Soto, Connor Quinn, Alicia Harbin, Elizabeth Bortolon, Xin Chen, Roy Haskell, Eva Lin, Shang-Fan Yu, Geoff Del-Rosario, Emily Chen, Scott Martin, Mark Merchant, Matthew Grimmer, Fabio Broccatelli, Jing Wang, Jennifer Pizzano, Peter Dragovich, Michael Berlin
The mammalian SWI/SNF helicase SMARCA4 is frequently mutated in cancer and inactivation results in a cellular dependence on its paralog, SMARCA2, thus making SMARCA2 an attractive synthetic lethal target. However, published data indicates that achiev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b8783755213f705053a27bfb6fa4879
https://doi.org/10.21203/rs.3.rs-1133243/v1
https://doi.org/10.21203/rs.3.rs-1133243/v1
Autor:
Jalila Adnane, Yong S. Chang, Scott Wilhelm, Arris J. Henderson, Elizabeth Bortolon, Mark Lynch, Joan Levy, Dahai Xue, Charles Chen, Ian C. A. Taylor, Marina Ichetovkin, Dean Wilkie, Angela McNabola, Christopher A. Carter, Pamela A. Trail
Publikováno v:
Cancer Chemotherapy and Pharmacology. 59:561-574
New research findings have revealed a key role for vascular endothelial growth factor (VEGF) in the stimulation of angiogenesis in clear cell renal carcinoma (RCC) which is a highly vascularized and treatment-resistant tumor. Sorafenib (BAY 43-9006,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e983d828733645a8789daff5a44a0f7
https://doi.org/10.1007/s00280-006-0393-4
https://doi.org/10.1007/s00280-006-0393-4